Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Official Asks Industry to Discuss Candidates for Essential Medicines
March 18, 2016
- Kamoya Prods Regulatory Science Society to Compile Essential Drug List
March 17, 2016
- Whether to Draw Line between 15 Billion and 100 Billion Yen Sales Thresholds for Re-Pricing Will Hold Key: Kamoya, Nakai
March 17, 2016
- Coefficient for New Generic Pricing “Will Decline Further” if Business Practices Are Not Changed: JGA Official
March 17, 2016
- Opdivo Gets Orphan Status for Hodgkin’s Lymphoma
March 17, 2016
- Nobelpharma CEO Says Sakigake System “Very Helpful”
March 17, 2016
- PMDA Had 43 Advanced Regulatory Advisory Sessions with Startups, Academia in FY2015
March 16, 2016
- Vaccine Panel Wary about Including Synflorix in Public Immunization Program
March 16, 2016
- Oculomucocutaneous Syndrome, Erythema Multiforme Added to ADR List for Halaven
March 16, 2016
- MHLW to Require CTD-Based Submissions for Generics, Effective March 2017
March 15, 2016
- Sales Thresholds for Re-Pricing Rule to Be Key Point of Future Discussions: MHLW Pharma Management Director
March 15, 2016
- MHLW Panel Launches Discussions on New Basic Plan against Cancer
March 14, 2016
- MHLW Panel Roughly OKs Use of MID-NET Database by Drug Makers
March 14, 2016
- No Licensing Deal Clinched for First AMED-Backed Drug Seed
March 14, 2016
- MHLW’s Info Gathering System for Pediatric Drugs Goes Live
March 14, 2016
- Japan to Lead Initiatives to Disseminate Regulatory Submission, Review Rules in APEC
March 14, 2016
- MHLW Wants to Continue Price Maintenance Scheme for On-Patent Drugs: Shiozaki
March 11, 2016
- Shiozaki Seeks Understanding for “Huge-Seller” Drug Re-Pricing
March 11, 2016
- Drug Makers Should Have Freewheeling Discussions towards 2018 Reform, MHLW Wants to Pick Their Brains: Official
March 10, 2016
- “Huge Seller” Re-Pricing Dominates Discussions at LDP Study Group
March 10, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…